Does research into new Alzheimer's treatments reflect what matters most to those living with the disease and to their care partners? When new drugs become available, will they make the changes in people’s lives that are most important to them—or only help people do better on cognitive tests but not improve ability in areas of day-to-day living that are most important?

Surprisingly, patient and caregiver priorities have not been studied in a...

Is depression or anxiety a risk factor for Alzheimer’s disease – or the other way around? For our May 2018 Talk, we spoke with Jennifer R. Gatchel, MD, PhD, a geriatric psychiatrist at Massachusetts General Hospital and an instructor in psychiatry at Harvard Medical School.

Dr. Gatchel shared an overview of what we know, current theories on this topic, and insights from her own research, which has found...

For National Minority Health Month, our April Alzheimer's Talks focused on a first-of-its-kind study that used tailored text messaging to boost Alzheimer’s knowledge in African Americans—who are up to three times more likely than non-Hispanic whites to get Alzheimer’s. Do the findings point to ways to improve health information-seeking and health literacy about Alzheimer’s among high-risk communities of color?

Stephanie Monroe, Executive Director of our AfricanAmericansAgainstAlzheimer's network, spoke with Karen Lincoln,...

Demystifying clinical trials was the topic of our March Alzheimer’s Talk—how they work, what you need to know and why they’re important. UsAgainstAlzheimer’s Board Member and Author/Caregiver Advocate Meryl Comer moderated an insightful discussion with: Reisa Sperling, MD, Harvard neurology professor and project leader of the NIH-funded A4 Study, a first-of-its kind prevention trial in older adults with evidence of early Alzheimer’s but no symptoms; Geri Taylor, who...